Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States

J Occup Environ Med. 2008 Sep;50(9):998-1005. doi: 10.1097/JOM.0b013e3181715111.

Abstract

Objective: To assess the health care utilization and cost of illness for osteoarthritis (OA) patients taking pain medications. Specifically, the goals were to estimate the direct health care and indirect costs of OA.

Methods: A claims database of privately insured patients was used to identify OA patients. Prescription drug pain treatments included tramadol, cyclooxygenase-II inhibitors, and nonsteroidal anti-inflammatory drugs. Mean annual per patient costs were calculated from an employer's perspective.

Results: OA patients were prescribed multiple drugs simultaneously and/or sequentially to manage pain. OA patients had a number of prevalent comorbid conditions. Average annual direct medical, drug, and indirect work loss costs were $8601, $2941, and $4603, respectively.

Conclusions: There was a substantial payer burden associated with OA resulting from the drug, medical, and disability costs and OA-related comorbidities and high concomitant medication utilization.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics, Opioid / economics*
  • Anti-Inflammatory Agents, Non-Steroidal / economics*
  • Cost of Illness*
  • Costs and Cost Analysis
  • Cyclooxygenase 2 / economics*
  • Female
  • Humans
  • Insurance Claim Review
  • Insurance Coverage*
  • Male
  • Middle Aged
  • Osteoarthritis / drug therapy
  • Osteoarthritis / economics
  • Osteoarthritis / physiopathology*
  • Pain / drug therapy*
  • Tramadol / economics*
  • United States

Substances

  • Analgesics, Opioid
  • Anti-Inflammatory Agents, Non-Steroidal
  • Tramadol
  • Cyclooxygenase 2